Navidea (NAVB) Gets a Buy Rating from H.C. Wainwright
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Navidea (NAVB), with a price target of $6.00. The company’s shares closed last Friday at $2.46.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 13.6% and a 39.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Aridis Pharmaceuticals, and Achieve Life Sciences.
Currently, the analyst consensus on Navidea is a Moderate Buy with an average price target of $3.50, implying a 12.2% upside from current levels. In a report issued on May 16, Maxim Group also assigned a Buy rating to the stock with a $3.00 price target.
See today’s analyst top recommended stocks >>
Based on Navidea’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $156.3K and GAAP net loss of $2.67 million. In comparison, last year the company earned revenue of $41.62K and had a GAAP net loss of $2.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.